Denemek ALTIN - Özgür
Middle East: A rising powerhouse in Medtech and Diagnostics.
BioSpectrum Asia
|BioSpectrum Asia Feb 2025
The Middle East's medtech and diagnostics sector is undergoing a dynamic transformation, fuelled by rapid technological advancements and strategic healthcare investments.
-
Garima Malhotra, Associate Partner, Healthcare and Lifescence, Praxis Global Alliance
This burgeoning industry is poised for significant growth, driven by a convergence of regional and global trends. As the region continues to embrace innovation and prioritise healthcare, it is well on its way to becoming a global hub for medtech and diagnostics, attracting investment, fostering collaboration, and driving advancements that will shape the future of healthcare.
The global medtech market, valued at an impressive $640 billion, is on track to surpass $960 billion by 2030 growing at a CAGR of 7 per cent, signalling transformative growth in healthcare innovation. Amid this surge, the Middle East is emerging as a key player, with its medtech market projected to grow from $18 billion to over $27 billion by 2030 at a robust CAGR of 7 per cent. Similarly, the region's diagnostics market, currently worth $6 billion, is expected to exceed $8 billion by 2030, driven by a 6.5 per cent CAGR. This remarkable growth is fuelled by rising healthcare expenditures, a growing prevalence of chronic diseases, and government-led initiatives to modernise healthcare infrastructure.
Countries like Saudi Arabia and the UAE are spearheading this transformation with dedicated healthcare spending plans and a focus on cutting-edge technologies. Diagnostic imaging, minimally invasive surgery, and wearable devices are revolutionising healthcare delivery. Furthermore, advancements in artificial intelligence (AI) and telemedicine are reshaping the region's healthcare landscape.
Addressing regional needs
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Feb 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits
US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation
US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio
Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema
A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing
Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO
Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
IIT-D and AIIMS develop swallowable microdevice for microbiome study
Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Ambitious research to develop multivalent vaccines against multiple deadly filoviruses
Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.
1 min
BioSpectrum Asia Feb 2026
Listen
Translate
Change font size
